TABLE 2.

Primers used in the study

Primer	Sequencea	Application
P1	5′-TTGAATTCTTACTCCGCAAGGGGTAGTCTGTTG-3′	RTA exon1-intron-exon2, forward
P2	5′-TTAGATCTCCATTGGTGCAGCTGGTACAGTGTGCC-3′	RTA exon1-intron-exon2, reverse
P3	5′-TTGGATCCGTGAGCAAGGGCGCCGAGCTGTTC-3′	GFP ORF, forward
P4	5′-TCGCGGCCGCTCACTTGTACAGCTC-3′	GFP ORF, reverse
P5	5′-TCAGGAGAGTTAGGGCCGTGCTGATTATG-3′	m6A site A mutation
P6	5′-CGTGCTGATTATGTGGCCAAGCTTCTGCTCG-3′	m6A site B mutation
P7	5′-GCGGAGACGGCCGGCCGCTCCCACAAAA-3′	m6A site C mutation
P8	5′-TTGTCGGTGCTGGCCCAATATCTGAATGG-3′	m6A site D mutation
P9	5′-GGGTGGCGACGGCCAGGGTATCTAAC-3′	m6A site E mutation
P10	5′-TATCTGATCCCAGGCCGGTAATGATACC-3′	m6A site F mutation
P11	5′-CTTCGTCGGCCTCTCGGCCGAACTGAAGGC-3′	m6A site G mutation
P12	5′-CCTCTCGAATGAGGCCCAAAGGCGCGG-3′	m6A site H mutation
P13	5′-GCAAGGTCACTGGCCTGTCCTATCCAGG-3′	m6A site I mutation
P14	5′-TCCTGGAGCCAGGCCTGTTGCCGGCTTC-3′	m6A site J mutation
P15	5′-AGGCACCACTCTGTGCAGTCCGC-3′	RTA pre-mRNA, forward
P16	5′-TCCCTGCAGCAGTTGTACAAACTTG-3′	RTA pre-mRNA, reverse
P17	5′-CCATTGGTGCAGCTGGTACAGTGTGCC-3′	RTA pre-mRNA cDNA synthesis
P18	5′-GAACAGTCGGGTGTCAGGGCTC-3′	CLIPb–qRT-PCR, site A, forward
P19	5′-GCGGTGCATTTACGAGCAGAAG-3′	CLIP–qRT-PCR, site A, reverse
P20	5′-GGCAGTCTGGATTGAGGGTG-3′	CLIP–qRT-PCR, site F, forward
P21	5′-GGAGAGAGTGGCGTGTCATAG-3′	CLIP–qRT-PCR, site F, reverse
P22	5′-GCTTCGGCGGTCCTGTGTGG-3′	CLIP–qRT-PCR, site G, forward
P23	5′-TTAGGTCACTGGGATCGTAG-3′	CLIP–qRT-PCR, site G, reverse
P24	5′-GTTGTGATGGCTGACCCACCCTG-3′	METTL3 mRNA, forward
P25	5′-GGTTCAACCAGTGACCTGTACGGC-3′	METTL3 mRNA, reverse
P26	5′-TCTGACCCCCAAAGATGATG-3′	FTO mRNA, forward
P27	5′-CTCGGAGAATTAGTTTAGGATATTTCA-3′	FTO mRNA, reverse
P28	5′-ATTGCCGACAGGATGCAGA-3′	β-Actin mRNA, forward
P29	5′-GAGTACTTGCGCTCAGGAGGA-3′	β-Actin mRNA, reverse

^am⁶A sites with an A → C mutation are highlighted in bold.

^bCLIP, UV cross-linking and immunoprecipitation.